These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 20848510)

  • 1. Therapy with anti-TNFα antibody enhances number and function of Foxp3(+) regulatory T cells in inflammatory bowel diseases.
    Boschetti G; Nancey S; Sardi F; Roblin X; Flourié B; Kaiserlian D
    Inflamm Bowel Dis; 2011 Jan; 17(1):160-70. PubMed ID: 20848510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy.
    Li Z; Vermeire S; Bullens D; Ferrante M; Van Steen K; Noman M; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2015 Oct; 21(10):2418-28. PubMed ID: 26308438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease.
    Gibson DJ; Elliott L; McDermott E; Tosetto M; Keegan D; Byrne K; Martin ST; Rispens T; Cullen G; Mulcahy HE; Cheifetz AS; Moss AC; Robson SC; Doherty GA; Ryan EJ
    Inflamm Bowel Dis; 2015 Dec; 21(12):2806-14. PubMed ID: 26332314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNFα treatment.
    Veltkamp C; Anstaett M; Wahl K; Möller S; Gangl S; Bachmann O; Hardtke-Wolenski M; Länger F; Stremmel W; Manns MP; Schulze-Osthoff K; Bantel H
    Gut; 2011 Oct; 60(10):1345-53. PubMed ID: 21459928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients.
    Ueno A; Jijon H; Chan R; Ford K; Hirota C; Kaplan GG; Beck PL; Iacucci M; Fort Gasia M; Barkema HW; Panaccione R; Ghosh S
    Inflamm Bowel Dis; 2013 Nov; 19(12):2522-34. PubMed ID: 24097227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive and Gut-Reparative Functions of Human Type 1 T Regulatory Cells.
    Cook L; Stahl M; Han X; Nazli A; MacDonald KN; Wong MQ; Tsai K; Dizzell S; Jacobson K; Bressler B; Kaushic C; Vallance BA; Steiner TS; Levings MK
    Gastroenterology; 2019 Dec; 157(6):1584-1598. PubMed ID: 31513797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab.
    Li Z; Arijs I; De Hertogh G; Vermeire S; Noman M; Bullens D; Coorevits L; Sagaert X; Schuit F; Rutgeerts P; Ceuppens JL; Van Assche G
    Inflamm Bowel Dis; 2010 Aug; 16(8):1299-310. PubMed ID: 20196149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+CD127low FoxP3+ regulatory T cells in Crohn's disease.
    Khalili A; Ebrahimpour S; Maleki I; Abediankenari S; Afrouzi MM
    Rom J Intern Med; 2018 Sep; 56(3):158-166. PubMed ID: 29453928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease.
    Ricciardelli I; Lindley KJ; Londei M; Quaratino S
    Immunology; 2008 Oct; 125(2):178-83. PubMed ID: 18422560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of correlation between Treg quantification assays in inflammatory bowel disease patients.
    Brandhorst G; Petrova DT; Weigand S; Eberle C; von Ahsen N; Schmitz J; Schultze FC; Raddatz D; Karaus M; Oellerich M; Walson PD
    World J Gastroenterol; 2015 Mar; 21(11):3325-9. PubMed ID: 25805940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease.
    Hvas CL; Kelsen J; Agnholt J; Dige A; Christensen LA; Dahlerup JF
    Autoimmunity; 2010 Jun; 43(4):325-33. PubMed ID: 20298123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decrease of CD4(+) CD25(+) CD127(low) FoxP3(+) regulatory T cells with impaired suppressive function in untreated ulcerative colitis patients.
    Mohammadnia-Afrouzi M; Zavaran Hosseini A; Khalili A; Abediankenari S; Hosseini V; Maleki I
    Autoimmunity; 2015; 48(8):556-61. PubMed ID: 26333292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents.
    Guidi L; Felice C; Procoli A; Bonanno G; Martinelli E; Marzo M; Mocci G; Pugliese D; Andrisani G; Danese S; De Vitis I; Papa A; Armuzzi A; Rutella S
    Biomed Res Int; 2013; 2013():286368. PubMed ID: 24063002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab treatment in Crohn's disease does not induce early changes in regulatory T cells.
    Dige A; Hvas CL; Deleuran B; Kelsen J; Bendix-Struve M; Dahlerup JF; Agnholt J
    Scand J Gastroenterol; 2011 Oct; 46(10):1206-14. PubMed ID: 21793633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
    Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
    Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.
    Assa A; Hartman C; Weiss B; Broide E; Rosenbach Y; Zevit N; Bujanover Y; Shamir R
    J Crohns Colitis; 2013 Jun; 7(5):369-76. PubMed ID: 22483567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment.
    Keijsers RR; Joosten I; Hendriks AG; Koenen HJ; van Erp PE; van de Kerkhof PC
    Exp Dermatol; 2015 Jan; 24(1):65-7. PubMed ID: 25355140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.